Our work identifies PARP1,2 inhibition as a synthetic vulnerability and therapeutic opportunity for RB1-mutated osteosarcoma with additional evidence that deleterious RB1 mutation may be a biomarker for clinically relevant PARP1,2 inhibitor sensitivity in other cancers. Here, PARP1 is linked to osteosarcoma.